deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03441958

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma

Sponsor: Centre C3i

Conditions Multiple Myeloma
Interventions ECT-001 (UM171) expanded cord blood
Updated 14 times since 2018 Last updated: Feb 6, 2024 Started: Mar 7, 2018 Primary completion: Oct 28, 2023 Completion: Oct 17, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is ongoing. The trial is conducted by Centre C3i and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Mar 2024 · 23 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Mar 2026 · 6 months · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

14 versions recorded

  1. Mar 2026 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Apr 2022 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Feb 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre C3i
  • Ciusss de L'Est de l'Île de Montréal
  • ExCellThera inc.
Data source: Ciusss de L'Est de l'Île de Montréal

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations